Guard Therapeutics
29 SEK 0%Be the first to follow this company
Guard Therapeutics is a developer of pharmaceuticals in the field of oxidative stress. The company focuses primarily on the research, development, and commercialization of pharmaceuticals that are intended to prevent the occurrence and complications of acute kidney damage. In preclinical studies, pharmaceuticals have been shown to protect exposed tissue and support regenerative processes. Treatment of acute kidney injuries in conjunction with heart surgery is a priority in clinical development.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
GUARD
Daily low / high price
28.6 / 29.6
SEK
Market cap
349.62M SEK
Turnover
47.75K SEK
Volume
1.6K
Financial calendar
Interim report
2024-08-22
Interim report
2024-11-13
Annual report
2025-02-20
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Jan Ståhlberg | 16.4 % | 16.4 % |
M2 Asset Management AB | 11.0 % | 11.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Penser Access by Carnegie: Guard Therapeutics: Kassan påfylld – fokus på fas IIb-studie
Kallelse till extra bolagsstämma i Guard Therapeutics International AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools